NIMENRIX
PFIZER
Identification
- Active ingredient (INN)
- NEISSERIA MENINGITIDIS GROUPE (A POLYSACCHARIDE - C POLYSACCHARIDE - W-135 POLYSACCHARIDE - Y POLYSACCHARIDE * CONJUGUE A L'ANATOXINE TETANIQUE EN TANT QUE PREOTEINE VECTRICE)
- Internal code
- 13 U 530
- Country of Origin
- Belgium
- Pharmaceutical form
- Powder + Solvent for Injectable Sol.
- Prescription List
- Highly Regulated (List I)
- Packaging
- b/01 flacon de poudre + une seringue preremplie de solvant + 02 aiguilles
DAWA Clinical Workbench v2.0
Information may not be accurate. Always consult a physician, pharmacist, or specialist before acting on any data shown here.
Indications
The following four-year-olds are recommended for a dose of the first dose of the vaccine.
Adolescents who received the first dose of the vaccine at the age of 16 or do not need a dose of the first dose of the vaccine at the age of 16 years are recommended for a dose of the first dose of the vaccine at the age of 16.
Adolescents who received the first dose of the vaccine at the age of 16 or do not need a dose of the first dose of the vaccine at the age of 10 years are recommended for a vaccine of the following types: suffering from a rare immune disorder known as the deficiency of the integral ingredient (in English): Complement component deficiency (infection with the mixture of the mittenant); Use of a type of medicine known as the cassitelium (infamily) /dry (in the form of the casual) (in the form of the casualty, in the form of the casual) (in the form of the casual) of the casual (inum, in the form of the casal) of the cass (inum, in the form of the casal, in the form.
Associated Conditions
The vaccine for meningitis and pregnant and nursing women prevents pregnant and nursing women from obtaining meningitis vaccines in normal conditions, since no human clinical studies prove the safety of these vaccines during pregnancy or breastfeeding, but pregnant or nursing women at risk of contracting a meningitis vaccine can obtain the appropriate type of vaccine after consulting the competent doctor to determine whether the benefit exceeds the potential risk of using these vaccines.
The vaccine prevents children under two years of age who suffer from spleenlessness or HIV/AIDS from being replaced by Minctra vaccine from two months to 23 months.
The vaccine must be separated from the vaccine for Minactra and the vaccine for children, except for the following three-year-olds: the vaccine for children, to be used in the same way as the vaccine for children, to be administered in the same way as the vaccine for children.
Mechanism of Action
Mingnoccal vaccine (intensifies the soil of the soil) is a vaccine that helps to protect against bacterial meningitis, caused by a bacterial bacterial type known as meningitis or meningitis (in Neisseria meningides), and produces thin membrane in the brain and spinal cord, which is a serious life-threatening condition.
The meningitis vaccine is three types of meningitis vaccine, including: multiple diabetes meningitis vaccines, which contain several diabetes vaccines (in English: Polysaccharide vaccine type, vaccine type A, vaccine type C, vaccine type C, vaccine type C, vaccine type II (in trivalent), which contains two species of meningitis type, and it contains two species of bacteria, which are also used in the field of A, type C, and type Imogen, which contains two species of vaccines, and two types of soil, which are not used in the field of soil, and two species of A, C, C, C, C, C, C, C, C, C, C, C, C, C, C, C, C, C, C, C, C, C, C, C, C, C, C, C, C.